nodes	percent_of_prediction	percent_of_DWPC	metapath
Bepridil—ABCB1—Vismodegib—skin cancer	0.0645	0.394	CbGbCtD
Bepridil—CYP2D6—Vemurafenib—skin cancer	0.0481	0.293	CbGbCtD
Bepridil—ABCB1—Dactinomycin—skin cancer	0.0339	0.207	CbGbCtD
Bepridil—KCNQ1—ear—skin cancer	0.0202	0.0743	CbGeAlD
Bepridil—CACNA1A—nerve—skin cancer	0.0188	0.0688	CbGeAlD
Bepridil—ABCB1—Docetaxel—skin cancer	0.0175	0.107	CbGbCtD
Bepridil—CACNA1D—ear—skin cancer	0.014	0.0515	CbGeAlD
Bepridil—Superinfection—Fluorouracil—skin cancer	0.0115	0.0387	CcSEcCtD
Bepridil—Electrocardiogram QT prolonged—Vemurafenib—skin cancer	0.00865	0.0291	CcSEcCtD
Bepridil—CALM2—ear—skin cancer	0.00852	0.0313	CbGeAlD
Bepridil—CALM1—ear—skin cancer	0.00848	0.0311	CbGeAlD
Bepridil—CACNA2D2—neck—skin cancer	0.00741	0.0272	CbGeAlD
Bepridil—KCNQ1—neck—skin cancer	0.00716	0.0263	CbGeAlD
Bepridil—TNNC1—connective tissue—skin cancer	0.00632	0.0232	CbGeAlD
Bepridil—Emotional distress—Fluorouracil—skin cancer	0.00615	0.0207	CcSEcCtD
Bepridil—Skin irritation—Fluorouracil—skin cancer	0.00605	0.0203	CcSEcCtD
Bepridil—CALM2—nerve—skin cancer	0.00536	0.0197	CbGeAlD
Bepridil—CALM1—nerve—skin cancer	0.00534	0.0196	CbGeAlD
Bepridil—Sudden death—Fluorouracil—skin cancer	0.00511	0.0172	CcSEcCtD
Bepridil—ATP1A1—hair follicle—skin cancer	0.0051	0.0187	CbGeAlD
Bepridil—Sinus tachycardia—Docetaxel—skin cancer	0.00469	0.0157	CcSEcCtD
Bepridil—PDE1B—female reproductive system—skin cancer	0.00465	0.017	CbGeAlD
Bepridil—CALM2—endothelium—skin cancer	0.00457	0.0168	CbGeAlD
Bepridil—CALM1—endothelium—skin cancer	0.00455	0.0167	CbGeAlD
Bepridil—CALM2—hair follicle—skin cancer	0.00449	0.0165	CbGeAlD
Bepridil—CACNA1A—head—skin cancer	0.00445	0.0163	CbGeAlD
Bepridil—Gastrointestinal symptom NOS—Fluorouracil—skin cancer	0.00445	0.0149	CcSEcCtD
Bepridil—KCNQ1—mammalian vulva—skin cancer	0.00423	0.0155	CbGeAlD
Bepridil—CALM2—blood vessel—skin cancer	0.00421	0.0155	CbGeAlD
Bepridil—CALM1—blood vessel—skin cancer	0.00419	0.0154	CbGeAlD
Bepridil—Arthritis—Vemurafenib—skin cancer	0.00415	0.0139	CcSEcCtD
Bepridil—PDE1A—female reproductive system—skin cancer	0.00389	0.0143	CbGeAlD
Bepridil—PDE1B—head—skin cancer	0.00388	0.0142	CbGeAlD
Bepridil—CALM3—nipple—skin cancer	0.00388	0.0142	CbGeAlD
Bepridil—KCNQ1—female reproductive system—skin cancer	0.00362	0.0133	CbGeAlD
Bepridil—Arthritis—Imiquimod—skin cancer	0.00354	0.0119	CcSEcCtD
Bepridil—Cardiac failure—Imiquimod—skin cancer	0.00352	0.0118	CcSEcCtD
Bepridil—ATP1A1—nipple—skin cancer	0.00346	0.0127	CbGeAlD
Bepridil—ATP1A1—neck—skin cancer	0.00342	0.0126	CbGeAlD
Bepridil—Myalgia—Vismodegib—skin cancer	0.00335	0.0112	CcSEcCtD
Bepridil—CACNA1C—connective tissue—skin cancer	0.00328	0.012	CbGeAlD
Bepridil—PDE1A—head—skin cancer	0.00325	0.0119	CbGeAlD
Bepridil—CACNA2D2—head—skin cancer	0.00313	0.0115	CbGeAlD
Bepridil—CALM2—nipple—skin cancer	0.00305	0.0112	CbGeAlD
Bepridil—CACNA1H—female reproductive system—skin cancer	0.00304	0.0112	CbGeAlD
Bepridil—CALM1—nipple—skin cancer	0.00303	0.0111	CbGeAlD
Bepridil—KCNQ1—head—skin cancer	0.00302	0.0111	CbGeAlD
Bepridil—CALM2—neck—skin cancer	0.00301	0.0111	CbGeAlD
Bepridil—CALM1—neck—skin cancer	0.003	0.011	CbGeAlD
Bepridil—Influenza—Imiquimod—skin cancer	0.00297	0.00998	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00292	0.00981	CcSEcCtD
Bepridil—Dyspepsia—Vismodegib—skin cancer	0.00282	0.00948	CcSEcCtD
Bepridil—Decreased appetite—Vismodegib—skin cancer	0.00279	0.00936	CcSEcCtD
Bepridil—Gastrointestinal disorder—Vismodegib—skin cancer	0.00277	0.0093	CcSEcCtD
Bepridil—KCNH2—nipple—skin cancer	0.00276	0.0101	CbGeAlD
Bepridil—Constipation—Vismodegib—skin cancer	0.00274	0.00921	CcSEcCtD
Bepridil—Pain—Vismodegib—skin cancer	0.00274	0.00921	CcSEcCtD
Bepridil—Erectile dysfunction—Imiquimod—skin cancer	0.00274	0.00919	CcSEcCtD
Bepridil—PDE1B—lymph node—skin cancer	0.00272	0.00997	CbGeAlD
Bepridil—Depression—Imiquimod—skin cancer	0.00264	0.00887	CcSEcCtD
Bepridil—Gastrointestinal pain—Vismodegib—skin cancer	0.00262	0.00881	CcSEcCtD
Bepridil—TNNC1—lymph node—skin cancer	0.00261	0.00956	CbGeAlD
Bepridil—Cardiac disorder—Vemurafenib—skin cancer	0.00259	0.00869	CcSEcCtD
Bepridil—Abdominal pain—Vismodegib—skin cancer	0.00254	0.00851	CcSEcCtD
Bepridil—Arthritis—Bleomycin—skin cancer	0.00251	0.00844	CcSEcCtD
Bepridil—ATP1A1—connective tissue—skin cancer	0.00245	0.009	CbGeAlD
Bepridil—Rhinitis—Imiquimod—skin cancer	0.00238	0.00801	CcSEcCtD
Bepridil—Pharyngitis—Imiquimod—skin cancer	0.00236	0.00793	CcSEcCtD
Bepridil—ATP1A1—epithelium—skin cancer	0.00233	0.00854	CbGeAlD
Bepridil—CACNA1C—female reproductive system—skin cancer	0.00232	0.0085	CbGeAlD
Bepridil—Asthenia—Vismodegib—skin cancer	0.0023	0.00773	CcSEcCtD
Bepridil—PDE1A—lymph node—skin cancer	0.00228	0.00836	CbGeAlD
Bepridil—CALM3—mammalian vulva—skin cancer	0.00226	0.00831	CbGeAlD
Bepridil—Tinnitus—Imiquimod—skin cancer	0.00222	0.00745	CcSEcCtD
Bepridil—ATP1A1—skin of body—skin cancer	0.00221	0.00813	CbGeAlD
Bepridil—Diarrhoea—Vismodegib—skin cancer	0.00219	0.00737	CcSEcCtD
Bepridil—CACNA2D2—lymph node—skin cancer	0.00219	0.00804	CbGeAlD
Bepridil—CALM2—connective tissue—skin cancer	0.00216	0.00792	CbGeAlD
Bepridil—CALM1—connective tissue—skin cancer	0.00215	0.00789	CbGeAlD
Bepridil—Arrhythmia—Imiquimod—skin cancer	0.00212	0.00714	CcSEcCtD
Bepridil—Cough—Vemurafenib—skin cancer	0.00212	0.00712	CcSEcCtD
Bepridil—KCNQ1—lymph node—skin cancer	0.00212	0.00777	CbGeAlD
Bepridil—Liver function test abnormal—Dactinomycin—skin cancer	0.0021	0.00706	CcSEcCtD
Bepridil—CACNA1D—head—skin cancer	0.0021	0.00769	CbGeAlD
Bepridil—Myalgia—Vemurafenib—skin cancer	0.00207	0.00694	CcSEcCtD
Bepridil—CALM2—epithelium—skin cancer	0.00205	0.00752	CbGeAlD
Bepridil—CALM1—epithelium—skin cancer	0.00204	0.00749	CbGeAlD
Bepridil—Rash—Vismodegib—skin cancer	0.00202	0.00679	CcSEcCtD
Bepridil—Dermatitis—Vismodegib—skin cancer	0.00202	0.00679	CcSEcCtD
Bepridil—ATP1A1—mammalian vulva—skin cancer	0.00202	0.00741	CbGeAlD
Bepridil—CALM2—skin of body—skin cancer	0.00195	0.00716	CbGeAlD
Bepridil—Cardiac failure—Fluorouracil—skin cancer	0.00195	0.00653	CcSEcCtD
Bepridil—CALM1—skin of body—skin cancer	0.00194	0.00712	CbGeAlD
Bepridil—CACNA1C—head—skin cancer	0.00193	0.0071	CbGeAlD
Bepridil—Nausea—Vismodegib—skin cancer	0.0019	0.0064	CcSEcCtD
Bepridil—Syncope—Imiquimod—skin cancer	0.00186	0.00624	CcSEcCtD
Bepridil—Palpitations—Imiquimod—skin cancer	0.00183	0.00614	CcSEcCtD
Bepridil—Loss of consciousness—Imiquimod—skin cancer	0.00182	0.00611	CcSEcCtD
Bepridil—Cough—Imiquimod—skin cancer	0.00181	0.00607	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00181	0.00606	CcSEcCtD
Bepridil—ATP1A1—lymphoid tissue—skin cancer	0.00179	0.00658	CbGeAlD
Bepridil—Hypertension—Imiquimod—skin cancer	0.00179	0.006	CcSEcCtD
Bepridil—CALM2—mammalian vulva—skin cancer	0.00178	0.00653	CbGeAlD
Bepridil—CACNA1H—lymph node—skin cancer	0.00178	0.00652	CbGeAlD
Bepridil—CALM1—mammalian vulva—skin cancer	0.00177	0.0065	CbGeAlD
Bepridil—Myalgia—Imiquimod—skin cancer	0.00176	0.00592	CcSEcCtD
Bepridil—Anxiety—Imiquimod—skin cancer	0.00176	0.0059	CcSEcCtD
Bepridil—ATP1A1—female reproductive system—skin cancer	0.00173	0.00635	CbGeAlD
Bepridil—Dry mouth—Imiquimod—skin cancer	0.00172	0.00579	CcSEcCtD
Bepridil—Decreased appetite—Vemurafenib—skin cancer	0.00172	0.00578	CcSEcCtD
Bepridil—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00171	0.00575	CcSEcCtD
Bepridil—Constipation—Vemurafenib—skin cancer	0.00169	0.00569	CcSEcCtD
Bepridil—Oedema—Imiquimod—skin cancer	0.00169	0.00568	CcSEcCtD
Bepridil—ABCB1—blood vessel—skin cancer	0.00167	0.00614	CbGeAlD
Bepridil—Shock—Imiquimod—skin cancer	0.00166	0.00558	CcSEcCtD
Bepridil—Erectile dysfunction—Temozolomide—skin cancer	0.00164	0.00551	CcSEcCtD
Bepridil—Hyperhidrosis—Imiquimod—skin cancer	0.00163	0.00549	CcSEcCtD
Bepridil—Anorexia—Imiquimod—skin cancer	0.00161	0.00541	CcSEcCtD
Bepridil—Angina pectoris—Fluorouracil—skin cancer	0.0016	0.00537	CcSEcCtD
Bepridil—Depression—Temozolomide—skin cancer	0.00158	0.00532	CcSEcCtD
Bepridil—CALM2—lymphoid tissue—skin cancer	0.00158	0.00579	CbGeAlD
Bepridil—CALM1—lymphoid tissue—skin cancer	0.00157	0.00577	CbGeAlD
Bepridil—Body temperature increased—Vemurafenib—skin cancer	0.00157	0.00526	CcSEcCtD
Bepridil—Pharyngitis—Dactinomycin—skin cancer	0.00156	0.00525	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00154	0.00517	CcSEcCtD
Bepridil—Insomnia—Imiquimod—skin cancer	0.00153	0.00513	CcSEcCtD
Bepridil—CALM2—female reproductive system—skin cancer	0.00152	0.00559	CbGeAlD
Bepridil—Paraesthesia—Imiquimod—skin cancer	0.00152	0.0051	CcSEcCtD
Bepridil—CALM1—female reproductive system—skin cancer	0.00152	0.00556	CbGeAlD
Bepridil—Dyspnoea—Imiquimod—skin cancer	0.00151	0.00506	CcSEcCtD
Bepridil—Somnolence—Imiquimod—skin cancer	0.0015	0.00505	CcSEcCtD
Bepridil—Dyspepsia—Imiquimod—skin cancer	0.00149	0.005	CcSEcCtD
Bepridil—Decreased appetite—Imiquimod—skin cancer	0.00147	0.00493	CcSEcCtD
Bepridil—CACNA1D—lymph node—skin cancer	0.00147	0.00538	CbGeAlD
Bepridil—Gastrointestinal disorder—Imiquimod—skin cancer	0.00146	0.0049	CcSEcCtD
Bepridil—ATP1A1—head—skin cancer	0.00144	0.0053	CbGeAlD
Bepridil—Pain—Imiquimod—skin cancer	0.00144	0.00485	CcSEcCtD
Bepridil—Asthenia—Vemurafenib—skin cancer	0.00142	0.00477	CcSEcCtD
Bepridil—Pharyngitis—Temozolomide—skin cancer	0.00141	0.00475	CcSEcCtD
Bepridil—Cardiac failure—Docetaxel—skin cancer	0.0014	0.00472	CcSEcCtD
Bepridil—Gastrointestinal pain—Imiquimod—skin cancer	0.00138	0.00464	CcSEcCtD
Bepridil—KCNH2—female reproductive system—skin cancer	0.00138	0.00506	CbGeAlD
Bepridil—Diarrhoea—Vemurafenib—skin cancer	0.00136	0.00455	CcSEcCtD
Bepridil—CACNA1C—lymph node—skin cancer	0.00135	0.00497	CbGeAlD
Bepridil—Abdominal pain—Imiquimod—skin cancer	0.00134	0.00449	CcSEcCtD
Bepridil—Body temperature increased—Imiquimod—skin cancer	0.00134	0.00449	CcSEcCtD
Bepridil—Tinnitus—Temozolomide—skin cancer	0.00133	0.00446	CcSEcCtD
Bepridil—Cardiac disorder—Temozolomide—skin cancer	0.00132	0.00444	CcSEcCtD
Bepridil—Rhinitis—Fluorouracil—skin cancer	0.00132	0.00442	CcSEcCtD
Bepridil—Dizziness—Vemurafenib—skin cancer	0.00131	0.0044	CcSEcCtD
Bepridil—Pharyngitis—Fluorouracil—skin cancer	0.0013	0.00438	CcSEcCtD
Bepridil—Cough—Bleomycin—skin cancer	0.00128	0.00431	CcSEcCtD
Bepridil—CALM2—head—skin cancer	0.00127	0.00467	CbGeAlD
Bepridil—CALM1—head—skin cancer	0.00127	0.00465	CbGeAlD
Bepridil—Liver function test abnormal—Docetaxel—skin cancer	0.00126	0.00425	CcSEcCtD
Bepridil—Myalgia—Bleomycin—skin cancer	0.00125	0.00421	CcSEcCtD
Bepridil—Rash—Vemurafenib—skin cancer	0.00125	0.0042	CcSEcCtD
Bepridil—Dermatitis—Vemurafenib—skin cancer	0.00125	0.00419	CcSEcCtD
Bepridil—Headache—Vemurafenib—skin cancer	0.00124	0.00417	CcSEcCtD
Bepridil—Asthenia—Imiquimod—skin cancer	0.00121	0.00407	CcSEcCtD
Bepridil—Oedema—Bleomycin—skin cancer	0.0012	0.00403	CcSEcCtD
Bepridil—Nausea—Vemurafenib—skin cancer	0.00118	0.00395	CcSEcCtD
Bepridil—Arrhythmia—Fluorouracil—skin cancer	0.00117	0.00394	CcSEcCtD
Bepridil—Vision blurred—Temozolomide—skin cancer	0.00117	0.00393	CcSEcCtD
Bepridil—Myalgia—Dactinomycin—skin cancer	0.00117	0.00392	CcSEcCtD
Bepridil—Tremor—Temozolomide—skin cancer	0.00116	0.0039	CcSEcCtD
Bepridil—Diarrhoea—Imiquimod—skin cancer	0.00116	0.00388	CcSEcCtD
Bepridil—Angina pectoris—Docetaxel—skin cancer	0.00115	0.00387	CcSEcCtD
Bepridil—KCNH2—head—skin cancer	0.00115	0.00423	CbGeAlD
Bepridil—Anorexia—Bleomycin—skin cancer	0.00114	0.00384	CcSEcCtD
Bepridil—CALM3—lymph node—skin cancer	0.00113	0.00416	CbGeAlD
Bepridil—Oedema—Dactinomycin—skin cancer	0.00112	0.00376	CcSEcCtD
Bepridil—Dizziness—Imiquimod—skin cancer	0.00112	0.00375	CcSEcCtD
Bepridil—Vertigo—Temozolomide—skin cancer	0.00111	0.00374	CcSEcCtD
Bepridil—Palpitations—Temozolomide—skin cancer	0.0011	0.00368	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00109	0.00367	CcSEcCtD
Bepridil—Cough—Temozolomide—skin cancer	0.00108	0.00364	CcSEcCtD
Bepridil—Paraesthesia—Bleomycin—skin cancer	0.00108	0.00362	CcSEcCtD
Bepridil—Vision blurred—Fluorouracil—skin cancer	0.00108	0.00362	CcSEcCtD
Bepridil—Hypertension—Temozolomide—skin cancer	0.00107	0.0036	CcSEcCtD
Bepridil—Dyspnoea—Bleomycin—skin cancer	0.00107	0.00359	CcSEcCtD
Bepridil—Anorexia—Dactinomycin—skin cancer	0.00107	0.00358	CcSEcCtD
Bepridil—Rash—Imiquimod—skin cancer	0.00107	0.00358	CcSEcCtD
Bepridil—Dermatitis—Imiquimod—skin cancer	0.00106	0.00357	CcSEcCtD
Bepridil—Headache—Imiquimod—skin cancer	0.00106	0.00356	CcSEcCtD
Bepridil—Myalgia—Temozolomide—skin cancer	0.00106	0.00355	CcSEcCtD
Bepridil—Anxiety—Temozolomide—skin cancer	0.00105	0.00354	CcSEcCtD
Bepridil—Decreased appetite—Bleomycin—skin cancer	0.00104	0.0035	CcSEcCtD
Bepridil—Dry mouth—Temozolomide—skin cancer	0.00103	0.00347	CcSEcCtD
Bepridil—Pain—Bleomycin—skin cancer	0.00103	0.00345	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00102	0.00343	CcSEcCtD
Bepridil—Oedema—Temozolomide—skin cancer	0.00101	0.0034	CcSEcCtD
Bepridil—ATP1A1—lymph node—skin cancer	0.00101	0.00371	CbGeAlD
Bepridil—Nausea—Imiquimod—skin cancer	0.001	0.00337	CcSEcCtD
Bepridil—Hyperhidrosis—Temozolomide—skin cancer	0.000979	0.00329	CcSEcCtD
Bepridil—Myalgia—Fluorouracil—skin cancer	0.000973	0.00327	CcSEcCtD
Bepridil—Decreased appetite—Dactinomycin—skin cancer	0.000973	0.00327	CcSEcCtD
Bepridil—Anorexia—Temozolomide—skin cancer	0.000965	0.00324	CcSEcCtD
Bepridil—Pain—Dactinomycin—skin cancer	0.000957	0.00322	CcSEcCtD
Bepridil—Rhinitis—Docetaxel—skin cancer	0.00095	0.00319	CcSEcCtD
Bepridil—Body temperature increased—Bleomycin—skin cancer	0.000949	0.00319	CcSEcCtD
Bepridil—Pharyngitis—Docetaxel—skin cancer	0.000941	0.00316	CcSEcCtD
Bepridil—Oedema—Fluorouracil—skin cancer	0.000933	0.00313	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000923	0.0031	CcSEcCtD
Bepridil—Insomnia—Temozolomide—skin cancer	0.000916	0.00308	CcSEcCtD
Bepridil—Gastrointestinal pain—Dactinomycin—skin cancer	0.000915	0.00307	CcSEcCtD
Bepridil—Paraesthesia—Temozolomide—skin cancer	0.000909	0.00305	CcSEcCtD
Bepridil—Dyspnoea—Temozolomide—skin cancer	0.000903	0.00303	CcSEcCtD
Bepridil—Somnolence—Temozolomide—skin cancer	0.0009	0.00302	CcSEcCtD
Bepridil—Dyspepsia—Temozolomide—skin cancer	0.000891	0.00299	CcSEcCtD
Bepridil—CALM2—lymph node—skin cancer	0.000891	0.00327	CbGeAlD
Bepridil—Anorexia—Fluorouracil—skin cancer	0.000889	0.00299	CcSEcCtD
Bepridil—CALM1—lymph node—skin cancer	0.000887	0.00325	CbGeAlD
Bepridil—Abdominal pain—Dactinomycin—skin cancer	0.000885	0.00297	CcSEcCtD
Bepridil—Body temperature increased—Dactinomycin—skin cancer	0.000885	0.00297	CcSEcCtD
Bepridil—Decreased appetite—Temozolomide—skin cancer	0.00088	0.00296	CcSEcCtD
Bepridil—Cardiac disorder—Docetaxel—skin cancer	0.00088	0.00295	CcSEcCtD
Bepridil—Gastrointestinal disorder—Temozolomide—skin cancer	0.000874	0.00294	CcSEcCtD
Bepridil—Pain—Temozolomide—skin cancer	0.000866	0.00291	CcSEcCtD
Bepridil—Constipation—Temozolomide—skin cancer	0.000866	0.00291	CcSEcCtD
Bepridil—Asthenia—Bleomycin—skin cancer	0.000861	0.00289	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00085	0.00285	CcSEcCtD
Bepridil—Arrhythmia—Docetaxel—skin cancer	0.000847	0.00284	CcSEcCtD
Bepridil—Insomnia—Fluorouracil—skin cancer	0.000844	0.00283	CcSEcCtD
Bepridil—CYP2D6—female reproductive system—skin cancer	0.000841	0.00309	CbGeAlD
Bepridil—Paraesthesia—Fluorouracil—skin cancer	0.000838	0.00281	CcSEcCtD
Bepridil—Dyspnoea—Fluorouracil—skin cancer	0.000832	0.00279	CcSEcCtD
Bepridil—Somnolence—Fluorouracil—skin cancer	0.000829	0.00279	CcSEcCtD
Bepridil—Gastrointestinal pain—Temozolomide—skin cancer	0.000828	0.00278	CcSEcCtD
Bepridil—Dyspepsia—Fluorouracil—skin cancer	0.000821	0.00276	CcSEcCtD
Bepridil—ABCB1—epithelium—skin cancer	0.000815	0.00299	CbGeAlD
Bepridil—Decreased appetite—Fluorouracil—skin cancer	0.000811	0.00272	CcSEcCtD
Bepridil—KCNH2—lymph node—skin cancer	0.000807	0.00296	CbGeAlD
Bepridil—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000805	0.00271	CcSEcCtD
Bepridil—Asthenia—Dactinomycin—skin cancer	0.000803	0.0027	CcSEcCtD
Bepridil—Abdominal pain—Temozolomide—skin cancer	0.0008	0.00269	CcSEcCtD
Bepridil—Body temperature increased—Temozolomide—skin cancer	0.0008	0.00269	CcSEcCtD
Bepridil—Pain—Fluorouracil—skin cancer	0.000798	0.00268	CcSEcCtD
Bepridil—Diarrhoea—Dactinomycin—skin cancer	0.000766	0.00257	CcSEcCtD
Bepridil—Rash—Bleomycin—skin cancer	0.000757	0.00254	CcSEcCtD
Bepridil—Dermatitis—Bleomycin—skin cancer	0.000756	0.00254	CcSEcCtD
Bepridil—Syncope—Docetaxel—skin cancer	0.00074	0.00249	CcSEcCtD
Bepridil—Body temperature increased—Fluorouracil—skin cancer	0.000738	0.00248	CcSEcCtD
Bepridil—Palpitations—Docetaxel—skin cancer	0.000729	0.00245	CcSEcCtD
Bepridil—Asthenia—Temozolomide—skin cancer	0.000726	0.00244	CcSEcCtD
Bepridil—Loss of consciousness—Docetaxel—skin cancer	0.000725	0.00244	CcSEcCtD
Bepridil—Cough—Docetaxel—skin cancer	0.00072	0.00242	CcSEcCtD
Bepridil—Nausea—Bleomycin—skin cancer	0.000713	0.00239	CcSEcCtD
Bepridil—Hypertension—Docetaxel—skin cancer	0.000712	0.00239	CcSEcCtD
Bepridil—ABCB1—mammalian vulva—skin cancer	0.000707	0.00259	CbGeAlD
Bepridil—Rash—Dactinomycin—skin cancer	0.000706	0.00237	CcSEcCtD
Bepridil—CYP2D6—head—skin cancer	0.000703	0.00258	CbGeAlD
Bepridil—Myalgia—Docetaxel—skin cancer	0.000702	0.00236	CcSEcCtD
Bepridil—Diarrhoea—Temozolomide—skin cancer	0.000693	0.00233	CcSEcCtD
Bepridil—Dry mouth—Docetaxel—skin cancer	0.000687	0.00231	CcSEcCtD
Bepridil—Oedema—Docetaxel—skin cancer	0.000673	0.00226	CcSEcCtD
Bepridil—Dizziness—Temozolomide—skin cancer	0.00067	0.00225	CcSEcCtD
Bepridil—Nausea—Dactinomycin—skin cancer	0.000665	0.00223	CcSEcCtD
Bepridil—Shock—Docetaxel—skin cancer	0.000662	0.00223	CcSEcCtD
Bepridil—Anorexia—Docetaxel—skin cancer	0.000642	0.00216	CcSEcCtD
Bepridil—Rash—Temozolomide—skin cancer	0.000638	0.00214	CcSEcCtD
Bepridil—Diarrhoea—Fluorouracil—skin cancer	0.000638	0.00214	CcSEcCtD
Bepridil—Dermatitis—Temozolomide—skin cancer	0.000638	0.00214	CcSEcCtD
Bepridil—Headache—Temozolomide—skin cancer	0.000634	0.00213	CcSEcCtD
Bepridil—ABCB1—lymphoid tissue—skin cancer	0.000628	0.0023	CbGeAlD
Bepridil—Dizziness—Fluorouracil—skin cancer	0.000617	0.00207	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000613	0.00206	CcSEcCtD
Bepridil—Insomnia—Docetaxel—skin cancer	0.000609	0.00205	CcSEcCtD
Bepridil—ABCB1—female reproductive system—skin cancer	0.000605	0.00222	CbGeAlD
Bepridil—Paraesthesia—Docetaxel—skin cancer	0.000605	0.00203	CcSEcCtD
Bepridil—Nausea—Temozolomide—skin cancer	0.000601	0.00202	CcSEcCtD
Bepridil—Dyspnoea—Docetaxel—skin cancer	0.0006	0.00202	CcSEcCtD
Bepridil—Somnolence—Docetaxel—skin cancer	0.000599	0.00201	CcSEcCtD
Bepridil—Dyspepsia—Docetaxel—skin cancer	0.000593	0.00199	CcSEcCtD
Bepridil—Rash—Fluorouracil—skin cancer	0.000588	0.00198	CcSEcCtD
Bepridil—Dermatitis—Fluorouracil—skin cancer	0.000588	0.00197	CcSEcCtD
Bepridil—Decreased appetite—Docetaxel—skin cancer	0.000585	0.00197	CcSEcCtD
Bepridil—Headache—Fluorouracil—skin cancer	0.000584	0.00196	CcSEcCtD
Bepridil—Gastrointestinal disorder—Docetaxel—skin cancer	0.000581	0.00195	CcSEcCtD
Bepridil—Pain—Docetaxel—skin cancer	0.000576	0.00193	CcSEcCtD
Bepridil—Constipation—Docetaxel—skin cancer	0.000576	0.00193	CcSEcCtD
Bepridil—Nausea—Fluorouracil—skin cancer	0.000554	0.00186	CcSEcCtD
Bepridil—Gastrointestinal pain—Docetaxel—skin cancer	0.000551	0.00185	CcSEcCtD
Bepridil—Abdominal pain—Docetaxel—skin cancer	0.000532	0.00179	CcSEcCtD
Bepridil—Body temperature increased—Docetaxel—skin cancer	0.000532	0.00179	CcSEcCtD
Bepridil—ABCB1—head—skin cancer	0.000506	0.00186	CbGeAlD
Bepridil—Asthenia—Docetaxel—skin cancer	0.000483	0.00162	CcSEcCtD
Bepridil—Diarrhoea—Docetaxel—skin cancer	0.000461	0.00155	CcSEcCtD
Bepridil—Dizziness—Docetaxel—skin cancer	0.000445	0.0015	CcSEcCtD
Bepridil—Rash—Docetaxel—skin cancer	0.000425	0.00143	CcSEcCtD
Bepridil—Dermatitis—Docetaxel—skin cancer	0.000424	0.00142	CcSEcCtD
Bepridil—Headache—Docetaxel—skin cancer	0.000422	0.00142	CcSEcCtD
Bepridil—Nausea—Docetaxel—skin cancer	0.0004	0.00134	CcSEcCtD
Bepridil—ABCB1—lymph node—skin cancer	0.000354	0.0013	CbGeAlD
Bepridil—CALM1—DAP12 signaling—IL6—skin cancer	6.98e-05	0.000263	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—CSPG4—skin cancer	6.98e-05	0.000263	CbGpPWpGaD
Bepridil—CALM3—Signaling by EGFR in Cancer—HRAS—skin cancer	6.97e-05	0.000262	CbGpPWpGaD
Bepridil—PDE1B—Innate Immune System—HRAS—skin cancer	6.95e-05	0.000261	CbGpPWpGaD
Bepridil—CALM3—Signaling by PDGF—HRAS—skin cancer	6.93e-05	0.000261	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—SUFU—skin cancer	6.86e-05	0.000258	CbGpPWpGaD
Bepridil—CALM1—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	6.86e-05	0.000258	CbGpPWpGaD
Bepridil—CALM2—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	6.86e-05	0.000258	CbGpPWpGaD
Bepridil—CALM1—DAP12 interactions—HRAS—skin cancer	6.86e-05	0.000258	CbGpPWpGaD
Bepridil—CALM2—DAP12 interactions—HRAS—skin cancer	6.86e-05	0.000258	CbGpPWpGaD
Bepridil—CALM2—Signaling by FGFR in disease—HRAS—skin cancer	6.86e-05	0.000258	CbGpPWpGaD
Bepridil—CALM1—Signaling by FGFR in disease—HRAS—skin cancer	6.86e-05	0.000258	CbGpPWpGaD
Bepridil—CALM2—Signaling by EGFR—HRAS—skin cancer	6.8e-05	0.000256	CbGpPWpGaD
Bepridil—CALM1—Signaling by EGFR—HRAS—skin cancer	6.8e-05	0.000256	CbGpPWpGaD
Bepridil—CALM3—Signaling by FGFR in disease—IL6—skin cancer	6.79e-05	0.000255	CbGpPWpGaD
Bepridil—CALM3—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	6.79e-05	0.000255	CbGpPWpGaD
Bepridil—CALM3—DAP12 interactions—IL6—skin cancer	6.79e-05	0.000255	CbGpPWpGaD
Bepridil—CACNA1C—Developmental Biology—IL6—skin cancer	6.77e-05	0.000255	CbGpPWpGaD
Bepridil—CALM2—Signaling by EGFR in Cancer—HRAS—skin cancer	6.74e-05	0.000254	CbGpPWpGaD
Bepridil—CALM1—Signaling by EGFR in Cancer—HRAS—skin cancer	6.74e-05	0.000254	CbGpPWpGaD
Bepridil—CALM3—Signaling by EGFR—IL6—skin cancer	6.73e-05	0.000253	CbGpPWpGaD
Bepridil—CALM2—Signaling by PDGF—HRAS—skin cancer	6.71e-05	0.000252	CbGpPWpGaD
Bepridil—CALM1—Signaling by PDGF—HRAS—skin cancer	6.71e-05	0.000252	CbGpPWpGaD
Bepridil—CALM3—Signaling by EGFR in Cancer—IL6—skin cancer	6.67e-05	0.000251	CbGpPWpGaD
Bepridil—PDE1B—Innate Immune System—IL6—skin cancer	6.65e-05	0.00025	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—SUFU—skin cancer	6.64e-05	0.00025	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—SUFU—skin cancer	6.64e-05	0.00025	CbGpPWpGaD
Bepridil—CALM3—Signaling by PDGF—IL6—skin cancer	6.64e-05	0.00025	CbGpPWpGaD
Bepridil—PDE1A—Signaling by GPCR—NRAS—skin cancer	6.62e-05	0.000249	CbGpPWpGaD
Bepridil—CALM3—Signaling by NGF—NRAS—skin cancer	6.6e-05	0.000248	CbGpPWpGaD
Bepridil—CALM3—Immune System—FOXO4—skin cancer	6.6e-05	0.000248	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—CSPG4—skin cancer	6.58e-05	0.000247	CbGpPWpGaD
Bepridil—CALM1—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	6.57e-05	0.000247	CbGpPWpGaD
Bepridil—CALM1—Signaling by FGFR in disease—IL6—skin cancer	6.57e-05	0.000247	CbGpPWpGaD
Bepridil—CALM2—DAP12 interactions—IL6—skin cancer	6.57e-05	0.000247	CbGpPWpGaD
Bepridil—CALM2—Signaling by FGFR in disease—IL6—skin cancer	6.57e-05	0.000247	CbGpPWpGaD
Bepridil—CALM2—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	6.57e-05	0.000247	CbGpPWpGaD
Bepridil—CALM1—DAP12 interactions—IL6—skin cancer	6.57e-05	0.000247	CbGpPWpGaD
Bepridil—PDE1B—Disease—PTGS2—skin cancer	6.57e-05	0.000247	CbGpPWpGaD
Bepridil—CALM3—B Cell Activation—HRAS—skin cancer	6.56e-05	0.000247	CbGpPWpGaD
Bepridil—CALM2—Signaling by EGFR—IL6—skin cancer	6.51e-05	0.000245	CbGpPWpGaD
Bepridil—CALM1—Signaling by EGFR—IL6—skin cancer	6.51e-05	0.000245	CbGpPWpGaD
Bepridil—CALM2—Signaling by EGFR in Cancer—IL6—skin cancer	6.45e-05	0.000243	CbGpPWpGaD
Bepridil—CALM1—Signaling by EGFR in Cancer—IL6—skin cancer	6.45e-05	0.000243	CbGpPWpGaD
Bepridil—CALM3—Transmission across Chemical Synapses—HRAS—skin cancer	6.43e-05	0.000242	CbGpPWpGaD
Bepridil—CALM1—Signaling by PDGF—IL6—skin cancer	6.42e-05	0.000242	CbGpPWpGaD
Bepridil—CALM2—Signaling by PDGF—IL6—skin cancer	6.42e-05	0.000242	CbGpPWpGaD
Bepridil—CALM2—Signaling by NGF—NRAS—skin cancer	6.39e-05	0.00024	CbGpPWpGaD
Bepridil—CALM1—Signaling by NGF—NRAS—skin cancer	6.39e-05	0.00024	CbGpPWpGaD
Bepridil—CALM1—Immune System—FOXO4—skin cancer	6.38e-05	0.00024	CbGpPWpGaD
Bepridil—CALM2—Immune System—FOXO4—skin cancer	6.38e-05	0.00024	CbGpPWpGaD
Bepridil—CALM2—B Cell Activation—HRAS—skin cancer	6.35e-05	0.000239	CbGpPWpGaD
Bepridil—CALM1—B Cell Activation—HRAS—skin cancer	6.35e-05	0.000239	CbGpPWpGaD
Bepridil—CALM3—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	6.28e-05	0.000236	CbGpPWpGaD
Bepridil—CALM3—Metabolism—ENO2—skin cancer	6.26e-05	0.000235	CbGpPWpGaD
Bepridil—PDE1A—Signaling Pathways—BRAF—skin cancer	6.22e-05	0.000234	CbGpPWpGaD
Bepridil—CALM2—Transmission across Chemical Synapses—HRAS—skin cancer	6.22e-05	0.000234	CbGpPWpGaD
Bepridil—CALM1—Transmission across Chemical Synapses—HRAS—skin cancer	6.22e-05	0.000234	CbGpPWpGaD
Bepridil—CALM3—Disease—FOXO4—skin cancer	6.09e-05	0.000229	CbGpPWpGaD
Bepridil—CALM2—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	6.08e-05	0.000229	CbGpPWpGaD
Bepridil—CALM1—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	6.08e-05	0.000229	CbGpPWpGaD
Bepridil—PDE1B—Signaling by GPCR—NRAS—skin cancer	6.06e-05	0.000228	CbGpPWpGaD
Bepridil—CALM2—Metabolism—ENO2—skin cancer	6.05e-05	0.000228	CbGpPWpGaD
Bepridil—CALM1—Metabolism—ENO2—skin cancer	6.05e-05	0.000228	CbGpPWpGaD
Bepridil—PDE1A—Immune System—NRAS—skin cancer	6.05e-05	0.000228	CbGpPWpGaD
Bepridil—CALM3—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	6.01e-05	0.000226	CbGpPWpGaD
Bepridil—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	5.95e-05	0.000224	CbGpPWpGaD
Bepridil—CALM2—Disease—FOXO4—skin cancer	5.89e-05	0.000222	CbGpPWpGaD
Bepridil—CALM1—Disease—FOXO4—skin cancer	5.89e-05	0.000222	CbGpPWpGaD
Bepridil—CALM1—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	5.81e-05	0.000219	CbGpPWpGaD
Bepridil—CALM2—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	5.81e-05	0.000219	CbGpPWpGaD
Bepridil—PDE1A—Signaling by GPCR—KRAS—skin cancer	5.7e-05	0.000214	CbGpPWpGaD
Bepridil—PDE1B—Signaling Pathways—BRAF—skin cancer	5.69e-05	0.000214	CbGpPWpGaD
Bepridil—CALM3—Signaling by NGF—KRAS—skin cancer	5.68e-05	0.000214	CbGpPWpGaD
Bepridil—CACNA1D—Metabolism—PTGS2—skin cancer	5.63e-05	0.000212	CbGpPWpGaD
Bepridil—PDE1A—Disease—NRAS—skin cancer	5.58e-05	0.00021	CbGpPWpGaD
Bepridil—PDE1B—Immune System—NRAS—skin cancer	5.53e-05	0.000208	CbGpPWpGaD
Bepridil—CALM2—Signaling by NGF—KRAS—skin cancer	5.5e-05	0.000207	CbGpPWpGaD
Bepridil—CALM1—Signaling by NGF—KRAS—skin cancer	5.5e-05	0.000207	CbGpPWpGaD
Bepridil—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	5.29e-05	0.000199	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—SHH—skin cancer	5.23e-05	0.000197	CbGpPWpGaD
Bepridil—PDE1B—Signaling by GPCR—KRAS—skin cancer	5.21e-05	0.000196	CbGpPWpGaD
Bepridil—PDE1A—Immune System—KRAS—skin cancer	5.21e-05	0.000196	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—RASA1—skin cancer	5.2e-05	0.000196	CbGpPWpGaD
Bepridil—PDE1B—Disease—NRAS—skin cancer	5.11e-05	0.000192	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—SHH—skin cancer	5.06e-05	0.00019	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—SHH—skin cancer	5.06e-05	0.00019	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—RASA1—skin cancer	5.03e-05	0.000189	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—RASA1—skin cancer	5.03e-05	0.000189	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—SMO—skin cancer	4.96e-05	0.000187	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—PTCH1—skin cancer	4.96e-05	0.000187	CbGpPWpGaD
Bepridil—CACNA1C—Metabolism—PTGS2—skin cancer	4.95e-05	0.000186	CbGpPWpGaD
Bepridil—CALM3—Neuronal System—HRAS—skin cancer	4.93e-05	0.000185	CbGpPWpGaD
Bepridil—PDE1A—Signaling by GPCR—HRAS—skin cancer	4.84e-05	0.000182	CbGpPWpGaD
Bepridil—CALM3—Signaling by NGF—HRAS—skin cancer	4.83e-05	0.000182	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—PTGER4—skin cancer	4.83e-05	0.000182	CbGpPWpGaD
Bepridil—PDE1A—Disease—KRAS—skin cancer	4.81e-05	0.000181	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—PTCH1—skin cancer	4.8e-05	0.000181	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—PTCH1—skin cancer	4.8e-05	0.000181	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—SMO—skin cancer	4.8e-05	0.000181	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—SMO—skin cancer	4.8e-05	0.000181	CbGpPWpGaD
Bepridil—CALM1—Neuronal System—HRAS—skin cancer	4.77e-05	0.000179	CbGpPWpGaD
Bepridil—CALM2—Neuronal System—HRAS—skin cancer	4.77e-05	0.000179	CbGpPWpGaD
Bepridil—PDE1B—Immune System—KRAS—skin cancer	4.76e-05	0.000179	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—ENO2—skin cancer	4.74e-05	0.000178	CbGpPWpGaD
Bepridil—CALM2—Signaling by NGF—HRAS—skin cancer	4.67e-05	0.000176	CbGpPWpGaD
Bepridil—CALM1—Signaling by NGF—HRAS—skin cancer	4.67e-05	0.000176	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—PTGER4—skin cancer	4.67e-05	0.000176	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—PTGER4—skin cancer	4.67e-05	0.000176	CbGpPWpGaD
Bepridil—PDE1A—Signaling by GPCR—IL6—skin cancer	4.64e-05	0.000174	CbGpPWpGaD
Bepridil—CALM3—Signaling by NGF—IL6—skin cancer	4.62e-05	0.000174	CbGpPWpGaD
Bepridil—CALM1—Signaling by NGF—IL6—skin cancer	4.47e-05	0.000168	CbGpPWpGaD
Bepridil—CALM2—Signaling by NGF—IL6—skin cancer	4.47e-05	0.000168	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—ENO2—skin cancer	4.47e-05	0.000168	CbGpPWpGaD
Bepridil—PDE1B—Signaling by GPCR—HRAS—skin cancer	4.43e-05	0.000167	CbGpPWpGaD
Bepridil—PDE1A—Immune System—HRAS—skin cancer	4.43e-05	0.000167	CbGpPWpGaD
Bepridil—PDE1B—Disease—KRAS—skin cancer	4.4e-05	0.000165	CbGpPWpGaD
Bepridil—CALM3—Disease—ERCC2—skin cancer	4.34e-05	0.000163	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—FOXO4—skin cancer	4.27e-05	0.000161	CbGpPWpGaD
Bepridil—PDE1B—Signaling by GPCR—IL6—skin cancer	4.24e-05	0.00016	CbGpPWpGaD
Bepridil—PDE1A—Immune System—IL6—skin cancer	4.24e-05	0.000159	CbGpPWpGaD
Bepridil—CALM1—Disease—ERCC2—skin cancer	4.2e-05	0.000158	CbGpPWpGaD
Bepridil—CALM2—Disease—ERCC2—skin cancer	4.2e-05	0.000158	CbGpPWpGaD
Bepridil—CALM3—Hemostasis—NRAS—skin cancer	4.18e-05	0.000157	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—FOXO4—skin cancer	4.13e-05	0.000155	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—FOXO4—skin cancer	4.13e-05	0.000155	CbGpPWpGaD
Bepridil—PDE1A—Disease—HRAS—skin cancer	4.09e-05	0.000154	CbGpPWpGaD
Bepridil—CALM3—Disease—TERT—skin cancer	4.07e-05	0.000153	CbGpPWpGaD
Bepridil—PDE1B—Immune System—HRAS—skin cancer	4.05e-05	0.000152	CbGpPWpGaD
Bepridil—CALM2—Hemostasis—NRAS—skin cancer	4.05e-05	0.000152	CbGpPWpGaD
Bepridil—CALM1—Hemostasis—NRAS—skin cancer	4.05e-05	0.000152	CbGpPWpGaD
Bepridil—CALM1—Disease—TERT—skin cancer	3.94e-05	0.000148	CbGpPWpGaD
Bepridil—CALM2—Disease—TERT—skin cancer	3.94e-05	0.000148	CbGpPWpGaD
Bepridil—PDE1A—Signaling Pathways—NRAS—skin cancer	3.91e-05	0.000147	CbGpPWpGaD
Bepridil—PDE1A—Disease—IL6—skin cancer	3.91e-05	0.000147	CbGpPWpGaD
Bepridil—PDE1B—Immune System—IL6—skin cancer	3.87e-05	0.000146	CbGpPWpGaD
Bepridil—CALM3—Innate Immune System—NRAS—skin cancer	3.77e-05	0.000142	CbGpPWpGaD
Bepridil—PDE1B—Disease—HRAS—skin cancer	3.74e-05	0.000141	CbGpPWpGaD
Bepridil—CALM1—Innate Immune System—NRAS—skin cancer	3.64e-05	0.000137	CbGpPWpGaD
Bepridil—CALM2—Innate Immune System—NRAS—skin cancer	3.64e-05	0.000137	CbGpPWpGaD
Bepridil—CALM3—Metabolism—ERCC2—skin cancer	3.64e-05	0.000137	CbGpPWpGaD
Bepridil—CALM3—Adaptive Immune System—NRAS—skin cancer	3.62e-05	0.000136	CbGpPWpGaD
Bepridil—CALM3—Hemostasis—KRAS—skin cancer	3.6e-05	0.000135	CbGpPWpGaD
Bepridil—PDE1B—Signaling Pathways—NRAS—skin cancer	3.58e-05	0.000135	CbGpPWpGaD
Bepridil—PDE1B—Disease—IL6—skin cancer	3.58e-05	0.000135	CbGpPWpGaD
Bepridil—CALM2—Metabolism—ERCC2—skin cancer	3.52e-05	0.000132	CbGpPWpGaD
Bepridil—CALM1—Metabolism—ERCC2—skin cancer	3.52e-05	0.000132	CbGpPWpGaD
Bepridil—CALM1—Adaptive Immune System—NRAS—skin cancer	3.5e-05	0.000132	CbGpPWpGaD
Bepridil—CALM2—Adaptive Immune System—NRAS—skin cancer	3.5e-05	0.000132	CbGpPWpGaD
Bepridil—CALM2—Hemostasis—KRAS—skin cancer	3.48e-05	0.000131	CbGpPWpGaD
Bepridil—CALM1—Hemostasis—KRAS—skin cancer	3.48e-05	0.000131	CbGpPWpGaD
Bepridil—PDE1A—Signaling Pathways—KRAS—skin cancer	3.37e-05	0.000127	CbGpPWpGaD
Bepridil—CALM3—Innate Immune System—KRAS—skin cancer	3.24e-05	0.000122	CbGpPWpGaD
Bepridil—CALM3—Disease—BRAF—skin cancer	3.22e-05	0.000121	CbGpPWpGaD
Bepridil—CALM3—Hemostasis—TP53—skin cancer	3.2e-05	0.00012	CbGpPWpGaD
Bepridil—CALM1—Innate Immune System—KRAS—skin cancer	3.14e-05	0.000118	CbGpPWpGaD
Bepridil—CALM2—Innate Immune System—KRAS—skin cancer	3.14e-05	0.000118	CbGpPWpGaD
Bepridil—CALM2—Disease—BRAF—skin cancer	3.12e-05	0.000117	CbGpPWpGaD
Bepridil—CALM1—Disease—BRAF—skin cancer	3.12e-05	0.000117	CbGpPWpGaD
Bepridil—CALM3—Adaptive Immune System—KRAS—skin cancer	3.11e-05	0.000117	CbGpPWpGaD
Bepridil—CALM2—Hemostasis—TP53—skin cancer	3.1e-05	0.000116	CbGpPWpGaD
Bepridil—CALM1—Hemostasis—TP53—skin cancer	3.1e-05	0.000116	CbGpPWpGaD
Bepridil—PDE1B—Signaling Pathways—KRAS—skin cancer	3.08e-05	0.000116	CbGpPWpGaD
Bepridil—CALM3—Hemostasis—HRAS—skin cancer	3.06e-05	0.000115	CbGpPWpGaD
Bepridil—CALM1—Adaptive Immune System—KRAS—skin cancer	3.01e-05	0.000113	CbGpPWpGaD
Bepridil—CALM2—Adaptive Immune System—KRAS—skin cancer	3.01e-05	0.000113	CbGpPWpGaD
Bepridil—PDE1A—Signaling Pathways—TP53—skin cancer	2.99e-05	0.000113	CbGpPWpGaD
Bepridil—CALM2—Hemostasis—HRAS—skin cancer	2.96e-05	0.000111	CbGpPWpGaD
Bepridil—CALM1—Hemostasis—HRAS—skin cancer	2.96e-05	0.000111	CbGpPWpGaD
Bepridil—PDE1A—Signaling Pathways—HRAS—skin cancer	2.86e-05	0.000108	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—TERT—skin cancer	2.85e-05	0.000107	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—TERT—skin cancer	2.76e-05	0.000104	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—TERT—skin cancer	2.76e-05	0.000104	CbGpPWpGaD
Bepridil—CALM3—Innate Immune System—HRAS—skin cancer	2.76e-05	0.000104	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—ERCC2—skin cancer	2.76e-05	0.000104	CbGpPWpGaD
Bepridil—PDE1A—Signaling Pathways—IL6—skin cancer	2.74e-05	0.000103	CbGpPWpGaD
Bepridil—PDE1B—Signaling Pathways—TP53—skin cancer	2.74e-05	0.000103	CbGpPWpGaD
Bepridil—CALM2—Innate Immune System—HRAS—skin cancer	2.67e-05	0.0001	CbGpPWpGaD
Bepridil—CALM1—Innate Immune System—HRAS—skin cancer	2.67e-05	0.0001	CbGpPWpGaD
Bepridil—CALM3—Adaptive Immune System—HRAS—skin cancer	2.65e-05	9.96e-05	CbGpPWpGaD
Bepridil—CALM3—Innate Immune System—IL6—skin cancer	2.64e-05	9.92e-05	CbGpPWpGaD
Bepridil—PDE1B—Signaling Pathways—HRAS—skin cancer	2.62e-05	9.85e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—PTGS2—skin cancer	2.6e-05	9.79e-05	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—ERCC2—skin cancer	2.6e-05	9.77e-05	CbGpPWpGaD
Bepridil—CALM2—Adaptive Immune System—HRAS—skin cancer	2.56e-05	9.63e-05	CbGpPWpGaD
Bepridil—CALM1—Adaptive Immune System—HRAS—skin cancer	2.56e-05	9.63e-05	CbGpPWpGaD
Bepridil—CALM1—Innate Immune System—IL6—skin cancer	2.55e-05	9.6e-05	CbGpPWpGaD
Bepridil—CALM2—Innate Immune System—IL6—skin cancer	2.55e-05	9.6e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—PTGS2—skin cancer	2.52e-05	9.47e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—PTGS2—skin cancer	2.52e-05	9.47e-05	CbGpPWpGaD
Bepridil—PDE1B—Signaling Pathways—IL6—skin cancer	2.5e-05	9.42e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling by GPCR—NRAS—skin cancer	2.4e-05	9.03e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling by GPCR—NRAS—skin cancer	2.32e-05	8.74e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling by GPCR—NRAS—skin cancer	2.32e-05	8.74e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—BRAF—skin cancer	2.26e-05	8.49e-05	CbGpPWpGaD
Bepridil—CALM3—Immune System—NRAS—skin cancer	2.19e-05	8.25e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—BRAF—skin cancer	2.18e-05	8.21e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—BRAF—skin cancer	2.18e-05	8.21e-05	CbGpPWpGaD
Bepridil—CALM3—Metabolism—PTGS2—skin cancer	2.18e-05	8.2e-05	CbGpPWpGaD
Bepridil—CALM2—Immune System—NRAS—skin cancer	2.12e-05	7.98e-05	CbGpPWpGaD
Bepridil—CALM1—Immune System—NRAS—skin cancer	2.12e-05	7.98e-05	CbGpPWpGaD
Bepridil—CALM2—Metabolism—PTGS2—skin cancer	2.11e-05	7.93e-05	CbGpPWpGaD
Bepridil—CALM1—Metabolism—PTGS2—skin cancer	2.11e-05	7.93e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling by GPCR—KRAS—skin cancer	2.07e-05	7.77e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—NRAS—skin cancer	2.03e-05	7.62e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling by GPCR—KRAS—skin cancer	2e-05	7.52e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling by GPCR—KRAS—skin cancer	2e-05	7.52e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—NRAS—skin cancer	1.96e-05	7.37e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—NRAS—skin cancer	1.96e-05	7.37e-05	CbGpPWpGaD
Bepridil—CALM3—Immune System—KRAS—skin cancer	1.89e-05	7.1e-05	CbGpPWpGaD
Bepridil—CALM2—Immune System—KRAS—skin cancer	1.83e-05	6.87e-05	CbGpPWpGaD
Bepridil—CALM1—Immune System—KRAS—skin cancer	1.83e-05	6.87e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling by GPCR—HRAS—skin cancer	1.76e-05	6.61e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—KRAS—skin cancer	1.74e-05	6.56e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling by GPCR—HRAS—skin cancer	1.7e-05	6.39e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling by GPCR—HRAS—skin cancer	1.7e-05	6.39e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—KRAS—skin cancer	1.69e-05	6.34e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—KRAS—skin cancer	1.69e-05	6.34e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling by GPCR—IL6—skin cancer	1.68e-05	6.33e-05	CbGpPWpGaD
Bepridil—ABCB1—Metabolism—PTGS2—skin cancer	1.65e-05	6.22e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling by GPCR—IL6—skin cancer	1.63e-05	6.12e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling by GPCR—IL6—skin cancer	1.63e-05	6.12e-05	CbGpPWpGaD
Bepridil—CALM3—Immune System—HRAS—skin cancer	1.6e-05	6.04e-05	CbGpPWpGaD
Bepridil—CYP2D6—Metabolism—PTGS2—skin cancer	1.56e-05	5.86e-05	CbGpPWpGaD
Bepridil—CALM1—Immune System—HRAS—skin cancer	1.55e-05	5.84e-05	CbGpPWpGaD
Bepridil—CALM2—Immune System—HRAS—skin cancer	1.55e-05	5.84e-05	CbGpPWpGaD
Bepridil—CALM3—Immune System—IL6—skin cancer	1.54e-05	5.78e-05	CbGpPWpGaD
Bepridil—CALM2—Immune System—IL6—skin cancer	1.49e-05	5.59e-05	CbGpPWpGaD
Bepridil—CALM1—Immune System—IL6—skin cancer	1.49e-05	5.59e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—HRAS—skin cancer	1.48e-05	5.57e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—HRAS—skin cancer	1.43e-05	5.39e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—HRAS—skin cancer	1.43e-05	5.39e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—NRAS—skin cancer	1.42e-05	5.34e-05	CbGpPWpGaD
Bepridil—CALM3—Disease—IL6—skin cancer	1.42e-05	5.34e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—NRAS—skin cancer	1.37e-05	5.16e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—NRAS—skin cancer	1.37e-05	5.16e-05	CbGpPWpGaD
Bepridil—CALM2—Disease—IL6—skin cancer	1.37e-05	5.16e-05	CbGpPWpGaD
Bepridil—CALM1—Disease—IL6—skin cancer	1.37e-05	5.16e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—KRAS—skin cancer	1.22e-05	4.59e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—KRAS—skin cancer	1.18e-05	4.44e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—KRAS—skin cancer	1.18e-05	4.44e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—TP53—skin cancer	1.08e-05	4.08e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—TP53—skin cancer	1.05e-05	3.95e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—TP53—skin cancer	1.05e-05	3.95e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—HRAS—skin cancer	1.04e-05	3.9e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—HRAS—skin cancer	1e-05	3.78e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—HRAS—skin cancer	1e-05	3.78e-05	CbGpPWpGaD
Bepridil—CALM3—Signaling Pathways—IL6—skin cancer	9.93e-06	3.74e-05	CbGpPWpGaD
Bepridil—CALM2—Signaling Pathways—IL6—skin cancer	9.61e-06	3.61e-05	CbGpPWpGaD
Bepridil—CALM1—Signaling Pathways—IL6—skin cancer	9.61e-06	3.61e-05	CbGpPWpGaD
